Weekly Top News – Psoriasis – July 22, 2019

July 22, 2019

Cosentyx (secukinumab) / Novartis
Secukinumab Treatment Led to Normalization of Quality of Life and Disease Symptoms in Psoriasis Patients with or without Prior Systemic Psoriasis Therapy: PROSE Study Results (EADV 2019) – Jul 16, 2019 – Abstract #P1632; Pres time: Oct 9, 2019; Location: e-Poster Hall; No abstract available.

 

BMS-986165 / BMS
An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study (EADV 2019) – Jul 16, 2019 – Abstract #P1621; Pres time: Oct 9, 2019; Location: e-Poster Hall; No abstract available.

 

mirikizumab (LY3074828) / Eli Lilly
Mirikizumab clinical trial estimate: First data from P3 trials OASIS-1 (NCT03482011) and OASIS-2 (NCT03535194) for psoriasis in 2021 (Cowen & Co) – Jul 20, 2019 – A subscription to Thomson ONE is required to gain full access to report 67616307; Page no: 318; REPORT TITLE: “Pharmaceutical industry pulse”; AUTHOR: Scala, Stephen, et al; DATE: 07/11/2019

 

Otezla (apremilast) / Celgene
Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: 32-Week Results From the Phase 3, STYLE Study (EADV 2019) – Jul 16, 2019 – Abstract #P1705; Pres time: Oct 9, 2019; Location: e-Poster Hall; No abstract available.

 

Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 reSURFACE 1 Study (EADV 2019) – Jul 16, 2019 – Abstract #P1653; Pres time: Oct 9, 2019; Location: e-Poster Hall; No abstract available.

 

Cosentyx (secukinumab) / Novartis
Cosentyx clinical trial estimate: Primary completion of P3 EXCEED trial (NCT02745080) for psoriatic arthritis in March 2020 and data in late 2019/2020 (Cowen & Co) – Jul 18, 2019 – A subscription to Thomson ONE is required to gain full access to report 67616307; Page no: 524, 587; REPORT TITLE: “Pharmaceutical industry pulse”; AUTHOR: Scala, Stephen, et al; DATE: 07/11/2019

 

Otezla (apremilast) / Celgene
FDA tentatively OKs Amneal’s generic Otezla (SeekingAlpha) – Jul 19, 2019 – “The FDA tentatively approves Amneal Pharmaceuticals’ (AMRX -3.5%) marketing application for a generic version of Celgene’s (CELG -0.5%) psoriasis med Otezla (apremilast).”

 

Cosentyx (secukinumab) / Novartis
Cosentyx: Regulatory submission for nrAxSpA in 2019 (Novartis) – Jul 18, 2019 – Q2 2019 Results: Regulatory submission for psoriatic arthritis in 2020  
[Screenshot]

No Comments

Post a Comment

Comment
Name
Email
Website